The association between tumor metabolism and tumor immunity has been extensively studied recently, and it has been found that tumor metabolic therapies can enhance the therapeutic effect of PD-1/PD-L1 pathway blockade by reversing the inhibitory TME. The gene discussed is CD274; the disease is neoplasm.